Lineage Operating Margin from 2010 to 2024
| LCTX Stock | USD 0.57 0.04 6.56% |
Check Lineage Cell financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lineage Cell's main balance sheet or income statement drivers, such as Depreciation And Amortization of 922.5 K, Interest Expense of 6 M or Total Revenue of 9.4 M, as well as many indicators such as Price To Sales Ratio of 19.99, Dividend Yield of 0.0015 or PTB Ratio of 3.12. Lineage financial statements analysis is a perfect complement when working with Lineage Cell Valuation or Volatility modules.
Lineage | Operating Margin |
Latest Lineage Cell's Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of Lineage Cell Therapeutics over the last few years. It is Lineage Cell's Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lineage Cell's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (4.17) % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
Lineage Operating Margin Regression Statistics
| Arithmetic Mean | (16.93) | |
| Coefficient Of Variation | (66.46) | |
| Mean Deviation | 9.88 | |
| Median | (19.57) | |
| Standard Deviation | 11.25 | |
| Sample Variance | 126.58 | |
| Range | 32.6818 | |
| R-Value | 0.13 | |
| Mean Square Error | 133.93 | |
| R-Squared | 0.02 | |
| Significance | 0.64 | |
| Slope | 0.33 | |
| Total Sum of Squares | 1,772 |
Lineage Operating Margin History
About Lineage Cell Financial Statements
Lineage Cell investors use historical fundamental indicators, such as Lineage Cell's Operating Margin, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Lineage Cell. Please read more on our technical analysis and fundamental analysis pages.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California. Lineage Cell operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 57 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Lineage Stock Analysis
When running Lineage Cell's price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.